AUA2018 Residents Forum - Wellness Burnout And Sustaining Your Career by American Urological Association

Immuno-Oncology: A Focus on Kidney Cancer is the third in the 4-part series. Topics will include "Review of Treatment Options for Systemic Disease", "Cytoeduction Debate" and "Impact of Immunotherapy on Treatment".

CME Available: https://auau.auanet.org/node/21355

Sequencing of Chemotherapy and Immunotherapy in Advanced Prostate Cancer: Present and Future is the fourth and final in a 4-part series. Topics will include "Role of Chemotherapy and Performance Status and Pain Management" and "Treatment Sequencing, Immunotherapy and Future Approaches".

CME Available: https://auau.auanet.org/node/19911

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.

The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.

Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - How to Properly Administer IO Therapies in an Infustion Suite is the third podcast in a 3-part series.

CME Available: https://auau.auanet.org/node/20964

Immuno-Oncology: A Focus on Bladder Cancer is the second in the 4-part series. Topics will include "non muscle invasive disease" and "muscle invasive disease" as well as "clinical trial evidence" and "future directions and biomarkers" of both.

CME Available: https://auau.auanet.org/node/21348

Speakers:

Christopher M. Gonzalez, MD, MBA

James M. Dupree, MD, MPH

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.

The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.

Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - Managing Patient Side Effects is the second podcast in a 3-part series.

CME Available: https://auau.auanet.org/node/20963

Immuno-Oncology: A New Class of Drugs is the first in the 4-part series. Topics will include "Tumor Immunotherapy", "Immunotherapy Drug Availability and Mechanisms of Action", "Vaccines", "Monoclonal Antibodies" and "Checkpoint Inhibitors".

CME Available: https://auau.auanet.org/node/21336

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New is the third podcast in a 4-part series. Topics will include "Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents" and "Radionuclide Therapy and Bone Health".

CME Available: auau.auanet.org/node/19909

Release date:

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.

The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.

Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - Biomarkers is the first podcast in a 3-part series.

CME Available: https://auau.auanet.org/node/20962